Impact of Invasive EEG Monitoring and Resective Neurosurgical Treatment on the Quality of Life in Patients with Drug Resistant Epilepsy - Preliminary Results

• Published in: Psychiatria Danubina Vol. 31; no. Suppl 5; pp. 769 - 773
• Main Authors: Mijatović, Dragana, Petelin Gadže, Željka, Đerke, Filip, Mrak, Goran, Petrović, Ratimir, Lekić, Andrica
• Format: Journal Article
• Language: English
• Published: Croatia 01-12-2019
• Subjects: Case-Control Studies; Drug Resistant Epilepsy - diagnosis; Drug Resistant Epilepsy - surgery; Electroencephalography; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Young Adult
• ISSN: 0353-5053

Neurosurgical treatment is one of important way to cure drug resistant epilepsy. After invasive EEG monitoring and the invasive neurosurgical treatment (resective surgery) there are possible complications (intracranial haemorrhage, cortical lesions and infections), however there are possible neuropsyhologic outcomes such as memory outcomes, language outcomes and psychiatric outcomes. The quality of life in epilepsy (QOLIE-31) scale is a self-completed questionnaire which contains seven subscales which address the following aspects: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects and overall quality of life. Our study aimed to examine the quality of life in patients with drug resistant epilepsy who had undergone invasive EEG monitoring and resective neurosurgical treatment through the application of the QOLIE-31 scale.
The study included 9 patients with drug resistant epilepsy who had undergone invasive EEG monitoring followed by resective neurosurgical treatment in the period from 2010 to 2016, and the control group of 15 patients with drug resistant epilepsy who had not undergone neurosurgical procedures. Clinical variables of interest for this study were obtained through phone contact, and the QOLIE-31 scale was applied.
In the domaine of seizure worry, patients in the examined group were more concerned about the seizures (54.7) compared to the examined group (80), as well as in the overal quality of life (examined group 57.5; control group 77.5). Patients in the control group complained more in the domain of antiepileptic therapy (score 70.7) than patients in the examined group (score 100). In the other domains: emotional well-being, energy/fatigue, cognitive functioning, and social functioning there were minor deviations between the examined and control groups.
There was no statistically significant difference between individual QOLIE-31 questionnaires, as well as between the two groups of respondents.